Mycosis fungoides and Sézary syndrome: the burden of pruritus
Author:
- Marie-France DemierreMDMarie-France Demierre
- 1 September 2010
- journal article
- Published by Elsevier in Community Oncology
- Vol. 7 (9) , 399-404
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Quality of life and psychological distress in patients with cutaneous lymphomaBritish Journal of Dermatology, 2009
- Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndromeBritish Journal of Dermatology, 2008
- Cowhage-Evoked Itch Is Mediated by a Novel Cysteine Protease: A Ligand of Protease-Activated ReceptorsThe Journal of Neuroscience, 2008
- The Pruritus Receptor Unit: A Target for Novel TherapiesJournal of Investigative Dermatology, 2007
- Clinical Classification of Itch: a Position Paper of the International Forum for the Study of ItchActa Dermato-Venereologica, 2007
- Significant impact of cutaneous T‐cell lymphoma on patients' quality of lifeCancer, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Neuropeptide Control Mechanisms in Cutaneous Biology: Physiological and Clinical SignificanceJournal of Investigative Dermatology, 2006
- Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2006
- Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndromeBlood, 2003